Peptide research, unfiltered
Read the research. Ignore the hype.
LetsTalkPeps is RN-reviewed peptide intelligence for biohackers, clinicians, and longevity scientists. Every claim is cited to primary literature and graded by how strong the evidence really is.
Evidence tiers
- Human RCT
Human RCT
Randomized controlled trials in humans
- Human data
Human data
Observational or mechanistic human studies
- Preclinical
Preclinical
Animal, cell, or in-silico models
- Anecdotal
Anecdotal
Case reports or community experience
Lead signal
pharmacokinetics
Antimicrobial Peptides: How Delivery Shapes Efficacy
Antimicrobial peptides show promise against drug-resistant bacteria, but delivery barriers limit their reach. Here's what preclinical research reveals.
Ian Gauntt, RN BSN · August 27, 2026 · 16 min read
Latest signals
View all →
guides
Oral GLP-1 Agonists: What Phase II Data Show
Ian Gauntt, RN BSN · Aug 26, 2026 · 13 min
A phase II trial of oral GLP-1 agonists found significant weight loss without injections. Here is what the VCT220 data show and what questions remain.
fundamentals
PTH 1-34: What Periodontitis Research Shows
Ian Gauntt, RN BSN · Aug 25, 2026 · 11 min
PTH 1-34 reduced bone loss and shifted immune balance in a preclinical periodontitis model. Here is what the research actually found and what remains unknown.
decision-framework
Real-World Drug Data: What Studies Actually Show
Ian Gauntt, RN BSN · Aug 24, 2026 · 14 min
Real-world drug data from five 2025 studies reveals how semaglutide, lecanemab, and upadacitinib perform outside controlled trials—and what the gaps mean.
fundamentals
GLP-1 Medicines: Beyond Weight Loss
Ian Gauntt, RN BSN · Aug 23, 2026 · 12 min
GLP-1 medicines do more than cut calories. Explore what preclinical and clinical research reveals about their weight-loss-independent actions.
decision-framework
GLP-1 Agonists: What New Research Shows
Ian Gauntt, RN BSN · Aug 22, 2026 · 14 min
GLP-1 agonists are showing up in surprising clinical contexts. Here's what new research shows about epilepsy, stoma care, and heart signals.
research
Romiplostim: What Research Shows
Ian Gauntt, RN BSN · Aug 21, 2026 · 14 min
Romiplostim research in immune thrombocytopenia: what a 2025 systematic review and meta-analysis found about efficacy and safety signals.
Peptide monographs
Cited profiles with evidence tiers and pharmacology notes.
growth
Human RCTACE-031
ACE-031 is a soluble activin receptor type IIB-Fc fusion protein that inhibits myostatin and related ligands. It has been tested in randomized trials for muscular dystrophy but is not approved for any use.
metabolic
PreclinicalAOD-9604
AOD-9604 is a synthetic peptide corresponding to amino acids 177-191 of human growth hormone. It has been investigated for fat metabolism in animals but has no established human efficacy for weight loss and is not approved by major regulators.
immune
Human RCTARA-290
ARA-290 (cibinetide) is an 11-amino-acid peptide that selectively activates the innate repair receptor. It has shown promise in Phase 2 trials for neuropathy and sarcoidosis-related fatigue but is not yet approved.
skin
Human dataArgireline
Argireline is a cosmetic peptide that inhibits SNARE complex formation and is marketed as a topical alternative to botulinum toxin for expression lines. Human cosmetic studies suggest modest wrinkle-reducing effects.
Newsletter
Get the signal before it gets noisy
New peptide research, decoded and cited. No marketing, no clinic spam.